Viatris Inc.
US · LEI 254900ZZTSW7NL773X71 · Figures of the company
Viatris Inc.: 24 links from the documents of the companies and the register.
Measures of Its Relationships
Counted on the company and the entities of its group, from the links below and their stated figures; a measure that the documents do not give is n/a. The same measures are in the file of the entity and in the answers of the tools.
- Lenders named
- 15
- Proven commitments
- none proven
- Largest lender
- none stated
- Lender concentration
- n/a
- Customers named
- 3
- Largest customer
- Cencora, Inc. 11% of revenue
- Named customers together
- 26%
- Customer concentration
- 36.4%
- Suppliers that name it
- 1
- Most dependent supplier
- Theravance Biopharma 100% of its revenue
- Owners named
- 0
- Largest owner
- none stated
- Holdings
- 0
the lender groups that the credit agreements of the company name, counted on the company and the entities of its group
the sum of the proven commitments of the lenders, in US dollars, at the dates of the agreements
the lender group with the largest proven commitments, with its share of the sum
the Herfindahl index of the proven commitments by lender group, as a fraction (1 for a single lender); null where no commitment is proven
the customers that the annual report of the company names as major customers
the named customer with the largest share of the revenue of the company, with that share
the sum of the stated shares of the named customers, as a fraction of the revenue of the company
the Herfindahl index of the stated shares of the named customers, as a fraction; null where no share is stated
the companies whose own annual report names the company as a major customer
the supplier for which the company is the largest share of revenue, with that share of the revenue of the supplier
the owners of the company or of an entity of its group outside the group
the owner with the largest stated interest, with that interest as a fraction
the entities outside the group that the company or its group owns
Lenders 15
Customers 3
| Entity | Figure | Evidence | Documents |
|---|---|---|---|
| Cencora, Inc. | 11% of the revenue of the supplier, fiscal year ended 31 Dec 2025 | Stated | Form 10-K for the fiscal year ended 31 December 2025 |
| McKesson Corporation | 10% of the revenue of the supplier, fiscal year ended 31 Dec 2023 | Stated | Form 10-K for the fiscal year ended 31 December 2025 |
| Cardinal Health, Inc. | 5% of the revenue of the supplier, fiscal year ended 31 Dec 2023 | Stated | Form 10-K for the fiscal year ended 31 December 2025 |
Suppliers 1
| Entity | Figure | Evidence | Documents |
|---|---|---|---|
| Theravance Biopharma | 100% of the revenue of the supplier, fiscal year ended 31 Dec 2025 | Stated | Form 10-K for the fiscal year ended 31 December 2025 |
Holdings 3
| Entity | Figure | Evidence | Documents |
|---|---|---|---|
| Mylan Luxembourg S.À R.L. | Consolidates the entity | Register | Record of MYLAN LUXEMBOURG S.À R.L. in the register of legal entities, 12 November 2026 |
| Mylan Pharmaceuticals Inc. | Consolidates the entity | Register | Record of Mylan Pharmaceuticals Inc. in the register of legal entities, 12 November 2026 |
| Utah Acquisition Sub Inc. | Consolidates the entity | Register | Record of Utah Acquisition Sub Inc. in the register of legal entities, 12 November 2026 |
Partners 2
| Entity | Figure | Evidence | Documents |
|---|---|---|---|
| Mapi Pharma Ltd. | Named as a collaboration partner | Stated | Form 10-K for the fiscal year ended 31 December 2025 |
| Theravance Biopharma | Named as a collaboration partner | Stated | Form 10-K for the fiscal year ended 31 December 2025 |
Each link names the documents that state it, with the class of its evidence: stated by one party, confirmed by both, or stated by the register of legal entities. A commitment is the commitment at the date of the agreement.